Medical Distribution. Scored on the same transparent model behind the daily rankings.
★
HSIC
Henry Schein, Inc. · Medical Distribution
52.7Score
$84.01Oct 9 close$9.4B
1Y Target$97.27Analyst consensus · 15 analysts
5Y Target$142.41Compound horizon
10Y Target$211.25Long-dated conviction
FCF$569mTTM · 06/26C+
FCF $569m — respectable but not differentiating · TTM from SEC filings (OCF − CapEx), four quarters to 06/26.
Rev+6.5%TTM YoYC+
Revenue +6.5% — steady but below market-beating range · Latest four quarters of revenue vs the four before them, from SEC filings.
D/E0.81C+
D/E 0.81 — above the Healthcare debt median (≈75th pctile)
P/E24.5xB
P/E 24.5 — near the Healthcare median (≈60th pctile)
PEG1.69C+
PEG 1.69 — modest premium; above fair value
Targets: 1-year is analyst consensus where covered, 5- and 10-year are model estimates; the DCF is a cross-check, not a target. Methodology
Quality-growth score · 52.7
Quality62.6
Growth61.3
Value38.2
Why this score
Buying back stock
Entry · Margin of safety
52-week rangeNear 52-week high
9% off the 12-month high
vs DCF fair value9% belowest. fair value ~$92
What the price assumes: free cash flow growing about 3% next year, rising to 4% a year by year ten — vs a starting rate of ~6% our model takes as the middle of three readings — analyst estimates, last year's revenue growth, and the company's own multi-year record.
Quality signals
Gross profitability37% · B+gross profit ÷ total assets — not in the score
ROIC11.6% · Breturn on invested capital — leads the quality score
Model-generatedFrom reported fundamentals, checked against the figures above · Editorial standards
Why now
Medical Distribution · market cap $9.4b. 9% off the 52-week high of $92.18. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $97.27 (implying +16% upside).
Moat
ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 141% of net income — earnings translate cleanly into cash.
Risk
Net margin 3.0% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Horizon
1-3 yr $97.27 (15-analyst consensus) — fundamentals + valuation re-rating. 5 yr $142.41 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $211.25 if current growth sustains into durable earnings power.
HSIC vs the Top Picks average
Pillar
HSIC
Book avg
Diff
Quality
63
83
-20
Growth
61
89
-28
Value
38
76
-38
Average of today's Top 30 (mean score 82.6); size and sector limits also decide the book.
Score history · HSIC
Trend
+1.6 over 81 daily scores
From 51.1 (Jun 22) → 52.7 (now)
One point per daily run; read From → To for the actual range.
HSIC at a glance
Same audited fundamentals as the score, unless a card says otherwise.
Analyst estimate revisions
30-day change
-0.3%
90-day change
+1.3%
Forward EPS estimate
$5.98
Over the last 90 days, what analysts expect HSIC to earn is drifting higher (+1.3%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
Estimates move both ways and are not part of the Bull Rankings score. Biggest movers →
Position sizing · HSIC
$
%
%
Shares to buy
23
Position size
$1,932
3.9% of portfolio
Stop price
$63.01
25% below $84.01
$ at risk if stopped
$483.06
budget $500.00 · 1% of portfolio
Math only: excludes commissions, slippage and gap risk. Inputs stay in your browser.
Henry Schein, Inc. (HSIC): score, valuation & FAQ
Henry Schein, Inc. (HSIC) is a Medical Distribution company that scores 52.7 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
On valuation, HSIC sits about 9% below our discounted-cash-flow fair value (a margin of safety) — the current price implies free cash flow growing about 3% next year, rising to 4% a year by year ten.
Is HSIC a good stock to buy?
Bull Rankings scores HSIC 52.7 out of 100 on its quality-growth model, which is a middling reading. A score is a quantitative screen of Henry Schein, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does HSIC score 52.7 on Bull Rankings?
The score leans on quality at 62.6 out of 100, with value the weakest pillar at 38.2 — the three combine geometrically, so a weak one cannot be papered over by a strong one. HSIC grades middle-of-pack across the graded signals. Each signal is graded against sector-aware thresholds rather than one absolute bar, so HSIC is measured against Medical Distribution peers, not against the market as a whole.
Is HSIC overvalued or undervalued?
Based on $84.01, HSIC sits about 9% below our discounted-cash-flow fair value (a margin of safety) — the current price implies free cash flow growing about 3% next year, rising to 4% a year by year ten. It trades at a 24.5x P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in HSIC?
Net margin 3.0% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.